Hungarian Conference on Alzheimer's Disease and Related Disorders 1998
News Coverage of the 4th Hungarian Conference on AD: Hungarian Conference on Alzheimer's Disease and Related Disorders 1998
ALL NEWS
6122 RESULTS
Sort By:
- Most Recent
- Most Commented
After a Summer of Icy Showers, What Will Happen with Buckets of Cash for ALS?
The ALS Ice Bucket Challenge has yielded more than $100 million—what research projects should get a share of the action?
CRISPR Gene Editing—Poised to Revolutionize Neuroscience?
A hot new tool, CRISPR empowers researchers to slice, dice, and add their own spice to any gene. Neuroscientists are starting to reap the benefits.
Neuroscientists Probe CRISPR Transgenics and Treatment Paradigms
Moving beyond cell culture, neuroscientists are using CRISPR to tweak genes in living animals and perhaps, one day, as therapy in humans.
Awards for Parkinson’s Disease Recognize Pioneering Treatments
Researchers in the United States, France, and Austria honored for pioneering work on deep-brain stimulation and L-dopa.
Inhibiting Neprilysin Is Good for the Heart: What About the Brain?
A new drug combination is better than standard therapy for congestive heart failure. It includes an inhibitor of neprilysin, a protease that digests Aβ in the brain.
Cerebrospinal Fluid Aβ Inches Closer to Bona Fide Diagnostic
When strict quality control standards are followed, low Aβ in cerebrospinal fluid accurately predicts amyloid plaques in people with cognitive impairment in clinical practice.
Ataxin 2 Variants Take Aim at Motor Neurons, Not Frontal Cortex
Expansions in ataxin 2 predispose people to the ALS end of the ALS-FTD spectrum, and never cause pure FTD, according to a new French study.
Benzodiazepines Boost Risk of Alzheimer’s Disease
Prescribed to treat anxiety and insomnia, benzodiazepines may do more than put the mind at ease. A new study links their prolonged use to increased Alzheimer’s risk.
Alzheimer Disease, Aging, and the Immune System
This past August, Alzheimer disease researchers met with colleagues from other fields and with foundation and NIH representatives in Bar Harbor, Maine, at the sixth annual workshop on Enabling Technologies for Alzheimer Disease Research.
Synaptic Function in Aging and AD
To what extent is AD an acceleration of normal aging? This decades-old question receded in favor of the view that AD is a separate process from normal aging when studies showed that patterns of neuronal loss are different in aging and AD.
High-throughput Assays (Application of OMICS to AD)
Genomic/proteomic/metabolomics (OMICS) research in AD remains in its infancy. Most studies stall after discovering lists of hundreds of genes whose expression changes in the chosen comparison.
Recommendations for Future Research
Recommendations for future research from the Enabling Technologies for Alzheimer's Disease Research in Bar Harbor (2006).
Enabling Technologies for Alzheimer Disease Research: 2006 Bar Harbor Workshop
Alzheimer Disease, Aging, and the Immune System Synaptic Function in Aging and AD High-throughput Assays (Application of OMICS to AD) Recommendations for Future Research Enabling Technologies for Alzheimer Disease Research: 2006 Bar Harbor Workshop
Overcompensation—It Could Work for the Brain
Overzealous neural responses may protect some amyloid-bearers from slipping into cognitive decline, a study suggests.
Current Filters
No filters selected